New Control Helps Monitor C. difficile Assays with Higher Confidence

A ready-to-use Clostridium difficile control set for use with human stool samples improves diagnostic assay performance-monitoring and reliability of results.

SeraCare Life Sciences, Inc. (Milford, MA, USA), a provider of products that help optimize performance across the in vitro diagnostics (IVD) lifecycle and bridge the gap between current diagnostic solutions and emerging technologies, has now added to its portfolio the “ACCURUN 501 C. difficile Control” – SeraCare’s first molecular control product targeting hospital acquired infections. The control set is formulated for use with IVD tests that detect C. difficile DNA in human stool samples and is ready-to-use in such tests with any transport system. Prepared from cultured Clostridium of 4 different strains or species delivered in a set of 4 vials, the bacteria are inactivated and in a human synthetic stool matrix.


"Hospital acquired infection assays present unique sample challenges which require dependable, whole cell controls. Our new ACCURUN 501 product is a full process control that is intended to not only estimate laboratory testing performance but also immediately detect analytical errors and monitor the entire testing process. As a result, our customers have greater confidence in fulfilling their QC requirements," said Christopher Long, product manager at SeraCare.

Related Links:
SeraCare Life Sciences
ACCURUN 501 C. difficile Control set